Rapafucin derivative compounds and methods of use thereof

US11945827B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11945827-B2
Application numberUS-202117332331-A
CountryUS
Kind codeB2
Filing dateMay 27, 2021
Priority dateFeb 4, 2016
Publication dateApr 2, 2024
Grant dateApr 2, 2024

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

First claim

Opening claim text (preview).

What is claimed is: 1. A compound of Formula (V) or an optically pure stereoisomer or pharmaceutically acceptable salt thereof, wherein L is optionally substituted (CH 2 ) n NR 20 C 1-6 alkylene; A is NH, NMe, O, S(O) 2 or S; each X is O; E is CH or N; R 1 is H; R 2 is C 1-20 alkoxy; R 3 is C 1-20 alkyl; R 4 is independently selected from the group consisting of H; or R 4 forms a cyclic structure formed with R 3 , the cyclic structure is C 2-10 heterocyclyl R 20 is H; n is 0; m is an integer selected from 2; p is 2; and q is 4. 2. The compound of claim 1 , wherein R 2 is methoxy. 3. The compound of claim 1 , wherein E is CH. 4. A pharmaceutical composition comprising the compound of claim 1 or an optically pure stereoisomer or pharmaceutically acceptable salt and a pharmaceutically acceptable carrier.

Assignees

Inventors

Classifications

  • C07D498/14Primary

    Ortho-condensed systems · CPC title

  • C07D498/04Primary

    Ortho-condensed systems · CPC title

  • the ester moiety containing a substituent or a structure which is considered as characteristic · CPC title

  • containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11945827B2 cover?
The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.
Who is the assignee on this patent?
Univ Johns Hopkins, Rapafusyn Pharmaceuticals Inc
What technology area does this patent fall under?
Primary CPC classification C07D498/14. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Apr 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 10 related publications on this page (citations in our corpus or others sharing the same primary CPC).